(Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

The initial launch of the Promega Plasmid Collection includes 300 plasmids available as traditional bacterial format or as purified DNA - a new service offering that strengthens Addgene’s growing ...

Abstract Summary Pharmacological enhancement of endoplasmic reticulum (ER) proteostasis is an attractive strategy to mitigate pathology linked to etiologically-diverse protein misfolding diseases.